• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.

作者信息

Zhu Chao, You Yun-Hong, Nie Ke-Ke, Ji You-Xin

机构信息

Department of Oncology, Qingdao Central Hospital, Second Affiliated Hospital of Qingdao University, Qingdao, Shandong 266042, China.

出版信息

Chin Med J (Engl). 2019 May 5;132(9):1115-1116. doi: 10.1097/CM9.0000000000000196.

DOI:10.1097/CM9.0000000000000196
PMID:31033571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6595879/
Abstract
摘要

相似文献

1
Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.埃克替尼联合奥希替尼克服了一名非小细胞肺癌患者的表皮生长因子受体19del/T790M/C797S/V834L四重耐药突变。
Chin Med J (Engl). 2019 May 5;132(9):1115-1116. doi: 10.1097/CM9.0000000000000196.
2
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report.厄洛替尼治疗奥希替尼获得性 EGFR 19del/C797S 突变介导耐药的肺腺癌患者 1 例报告
Anticancer Drugs. 2024 Sep 1;35(8):764-768. doi: 10.1097/CAD.0000000000001624. Epub 2024 Jul 16.
3
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.阿法替尼帮助克服 NSCLC 伴脑膜转移患者奥希替尼后继发性耐药，该患者存在获得性 EGFR L718Q 突变：一例报告。
BMC Cancer. 2019 Jul 17;19(1):702. doi: 10.1186/s12885-019-5915-7.
4
Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.贝伐珠单抗联合厄洛替尼克服非小细胞肺癌患者奥希替尼耐药。
Chin Med Sci J. 2019 Nov 12;34(4):292-296. doi: 10.24920/003487.
5
V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.V834L 和 L858R 突变与非小细胞肺癌对奥希替尼的反应相关。
JCO Precis Oncol. 2024 Jul;8:e2300215. doi: 10.1200/PO.23.00215.
6
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.非小细胞肺癌患者对奥希替尼获得性耐药：机制和临床结局。
J Cancer Res Clin Oncol. 2020 Sep;146(9):2427-2433. doi: 10.1007/s00432-020-03239-1. Epub 2020 May 8.
7
High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation.高通量测序揭示了具有新发性和获得性 EGFR T790M 突变的 NSCLC 的独特遗传特征和临床意义。
Lung Cancer. 2018 Oct;124:205-210. doi: 10.1016/j.lungcan.2018.08.014. Epub 2018 Aug 15.
8
[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].埃克替尼治疗老年晚期表皮生长因子受体基因突变非小细胞肺癌患者的临床疗效
Zhonghua Zhong Liu Za Zhi. 2019 Feb 23;41(2):152-153. doi: 10.3760/cma.j.issn.0253-3766.2019.02.014.
9
Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.奥希替尼在一名伴有软脑膜转移和EGFR罕见S768I突变患者中的疗效。
Lung Cancer. 2020 May;143:95-96. doi: 10.1016/j.lungcan.2020.03.016. Epub 2020 Mar 18.
10
Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.伴有G719A和原发性T790M表皮生长因子受体突变的非小细胞肺癌对一线奥希替尼治疗的反应
Clin Lung Cancer. 2019 Jul;20(4):e531-e533. doi: 10.1016/j.cllc.2019.05.002. Epub 2019 May 11.

引用本文的文献

1
Brain metastases from lung cancer: recent advances and novel therapeutic opportunities.肺癌脑转移：最新进展与新型治疗机遇
Discov Oncol. 2025 Feb 11;16(1):157. doi: 10.1007/s12672-025-01873-0.
2
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.基因突变谱分析揭示了非小细胞肺癌靶向治疗疗效和预后的生物标志物。
Heliyon. 2024 Mar 5;10(6):e27633. doi: 10.1016/j.heliyon.2024.e27633. eCollection 2024 Mar 30.

本文引用的文献

1
Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.中国患者使用下一代测序技术对奥希替尼耐药的非小细胞肺癌进行突变分析。
Biomed Res Int. 2018 Mar 11;2018:9010353. doi: 10.1155/2018/9010353. eCollection 2018.
2
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.肺腺癌伴 EGFR T790M 和 in trans C797S 对第一代和第三代 EGFR TKI 联合治疗有反应，并在耐药时改变等位基因构型。
J Thorac Oncol. 2017 Nov;12(11):1723-1727. doi: 10.1016/j.jtho.2017.06.017. Epub 2017 Jun 27.
3
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
第三代EGFR抑制剂治疗后获得的C797S突变的等位基因背景影响对后续治疗策略的敏感性。
Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. Epub 2015 May 11.
4
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.肺癌中酪氨酸激酶抑制剂耐药性发展的新兴模式。
J Clin Oncol. 2013 Nov 1;31(31):3987-96. doi: 10.1200/JCO.2012.45.2029. Epub 2013 Oct 7.
5
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
6
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.具有经典突变模式的复杂表皮生长因子受体（EGFR）突变的肺腺癌对吉非替尼反应良好。
Oncologist. 2008 Dec;13(12):1276-84. doi: 10.1634/theoncologist.2008-0093. Epub 2008 Dec 5.